Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
ib
Description:
The abbreviation “ib” is ambiguous in these titles and cannot be identified as a specific research concept or entity.
Related topic:
Lung Cancer Treatments and Mutations (12%)
OpenAlex ID:
keywords/ib
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012
·
George D Demetri
, Peter Reichardt
, et al.
·
The Lancet
·
1,523
PDF
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
2021
·
Chunfeng Xie
, Xu Zhou
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
225
PDF
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
2021
·
Matthew J Matasar
, Marcelo Capra
, et al.
·
The Lancet Oncology
·
147
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
2013
·
Ignace B. Vergote
, Antonio Jimeno
, et al.
·
Journal of Clinical Oncology
·
125
PDF
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021
·
R.A. Soo
, J.-Y. Han
, et al.
·
Annals of Oncology
·
117
C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
2023
·
Stephanie L. Wethington
, Payal D. Shah
, et al.
·
Clinical Cancer Research
·
105
PDF
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
2015
·
G. Deplanque
, M. Demarchi
, et al.
·
Annals of Oncology
·
103
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
2023
·
Dominik Dytfeld
, Tomasz Wróbel
, et al.
·
The Lancet Oncology
·
85
PDF
Comparable outcomes in chronic lymphocytic leukaemia ( CLL ) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study
2017
·
Anthony R. Mato
, Colleen Timlin
, et al.
·
British Journal of Haematology
·
66
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial
2024
·
Shinichi Imafuku
, Yukari Okubo
, et al.
·
The Journal of Dermatology
·
49
Interstitial nephritis in a patient taking sorafenib
2007
·
H. Izzedine
, I. Brocheriou
, et al.
·
Nephrology Dialysis Transplantation
·
46
The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials
2009
·
Paresh Soni
, Briton Shell
, et al.
·
Current Medical Research and Opinion
·
37
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
2025
·
Jaekyung Cheon
, Baek-Yeol Ryoo
, et al.
·
Liver Cancer
·
35
PDF
Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
2013
·
Gerald S. Falchook
, Aung Naing
, et al.
·
Oncotarget
·
35
PDF
Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
2008
·
A. Gradilone
, F. Pulcinelli
, et al.
·
Current Cancer Drug Targets
·
31
Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
2021
·
Samantha Wilkinson
, Alind Gupta
, et al.
·
JAMA Network Open
·
27
PDF
PKC-dependent extracellular signal-regulated kinase 1/2 pathway is involved in the inhibition of Ib on AngiotensinII-induced proliferation of vascular smooth muscle cells
2008
·
Yu Wang
, Tianhua Yan
, et al.
·
Biochemical and Biophysical Research Communications
·
22
Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of Pennsylvania
2005
·
Maria Luisa Veronese
, Kenneth Algazy
, et al.
·
Cancer Investigation
·
22
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML
2023
·
Toshiki Terao
, Ken-ichi Matsuoka
, et al.
·
Blood Advances
·
20
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging
2019
·
Shengfei Wang
, Xiaomin Niu
, et al.
·
Oncology Reports
·
19
PDF
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
2017
·
Jonathan A. Ledermann
, Andrew C. Embleton
, et al.
·
Journal of Clinical Oncology
·
19
Phase I trial of bortezomib in adults with recurrent malignant glioma
2006
·
S. Phuphanich
, J. Supko
, et al.
·
Journal of Clinical Oncology
·
19
Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia
2023
·
Aaron D. Goldberg
, Daniel Corum
, et al.
·
Blood
·
16
Solid-liquid phase equilibrium of Nintedanib in ten pure solvents: Determination, thermodynamic analysis, model correlation and molecular simulation
2021
·
Jinju Ma
, Huimin Li
, et al.
·
The Journal of Chemical Thermodynamics
·
16
Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK -positive ( ALK +) solid tumors in a histology-agnostic setting.
2021
·
Razelle Kurzrock
, Amy R. MacKenzie
, et al.
·
Journal of Clinical Oncology
·
16
Show more works
View as search
Works count:
177
Citation count:
3,304
Year
Topic
Type